Description: Mount Sinai Genomics, Inc., doing business as Sema4, develops and operates health intelligence software solution that helps in diagnosis, treatment, and prevention of disease. The company offers solutions, such as Sema4, a solution that helps in treatment of the diseases; Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology; Sema4 Signal, a solution that provides data driven care solutions with analytics, digital tools, and exome based somatic and hereditary cancer genomic test; Biopharma, a solution that offers portfolio of health information, pre-clinical and clinical trial support, analytics for actionable insights, and advance sequencing services. It offers noninvasive prenatal select, a blood test for determining baby's health; expanded carrier screen, a carrier screen for more than 280 inherited conditions if one is pregnant or planning for pregnancy; and CarrierCheck, a genetic screen for 67 inherited conditions to know how DNA could affect the children. The company also provides Natalis newborn screen, a home-test to know baby's health by screening for 193 childhood diseases; Solid Tumor panel to analyze cancer driven genes; and test catalogue, a comprehensive offering of genetic and genomic tests. In addition, it owns and operates Centrellis, an analytics platform that generate complete understanding of disease and wellness and extract individualized insights into human health, starting with reproductive health and oncology. The company's solutions include women's health, oncology, expanded carrier screen, noninvasive prenatal select, Natali's newborn screen, hereditary cancer. Mount Sinai Genomics, Inc. was incorporated in 2015 and is based in Stamford, Connecticut.
Home Page: www.sema4.com
SMFR Technical Analysis
North Tower
Stamford,
CT
06902
United States
Phone:
800 298 6470
Officers
| Name | Title |
|---|---|
| Mr. Jason Ryan | Exec. Chair of the Board |
| Mr. Isaac Ro | Consultant |
| Ms. Katherine A. Stueland | CEO & Director |
| Mr. Kevin Feeley | Sr. VP of Operations & CFO |
| Mr. Robert Sebra Ph.D. | VP of Technology Devel. |
| Dr. Matthew Davis Ph.D. | Chief Technology & Product Officer |
| Dr. Gustavo Stolovitzky Ph.D. | Chief Science Officer |
| Mr. Murali Mani | Chief Compliance & Privacy Officer |
| Ms. Karen White | Chief People Officer |
| Mr. Kareem M. Saad | Chief Transformation Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.553 |
| Price-to-Book MRQ: | 0.205 |
| Price-to-Sales TTM: | 0.4691 |
| IPO Date: | 2020-11-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 1200 |